PMID: 6986110Jan 1, 1980Paper

Controlled clinical trial of a new dosage form of metaproterenol

Annals of Allergy
G J Beck

Abstract

In a double-blind, crossover study of single doses an inhalant solution of metaproterenol was compared with an 0.5% solution of isoproterenol and placebo in nine patients with bronchial asthma and 13 patients with chronic obstructive pulmonary disease. The solutions were administered by IPPB in 15-minute treatment sessions. The mean duration of effect of metaproterenol, in terms of FEV1, and the magnitude of the FEV1 response to metaproterenol exceeded the isoproterenol data to a statistically significant degree, as did global ratings of response. FEF 25-75% and airway resistance showed similar patterns of response. Adverse experiences were minimal after both drugs.

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.